These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11697844)

  • 1. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
    Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
    Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
    Woloch C; Di Paolo A; Marouani H; Bocci G; Ciccolini J; Lacarelle B; Danesi R; Iliadis A
    Curr Top Med Chem; 2012; 12(15):1713-9. PubMed ID: 22978343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
    Bocci G; Danesi R; Allegrini G; Innocenti F; Di Paolo A; Falcone A; Conte PF; Del Tacca M
    Eur J Clin Pharmacol; 2002 Dec; 58(9):593-5. PubMed ID: 12602342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
    Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
    Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
    Di Paolo A; Ibrahim T; Danesi R; Maltoni M; Vannozzi F; Flamini E; Zoli W; Amadori D; Del Tacca M
    Ther Drug Monit; 2002 Oct; 24(5):588-93. PubMed ID: 12352929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.
    Maring JG; van Kuilenburg AB; Haasjes J; Piersma H; Groen HJ; Uges DR; Van Gennip AH; De Vries EG
    Br J Cancer; 2002 Apr; 86(7):1028-33. PubMed ID: 11953843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
    Di Paolo A; Danesi R; Ciofi L; Vannozzi F; Bocci G; Lastella M; Amatori F; Martelloni BM; Ibrahim T; Amadori D; Falcone A; Del Tacca M
    Ther Drug Monit; 2005 Jun; 27(3):362-8. PubMed ID: 15905808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
    Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
    Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
    Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population study of dihydropyrimidine dehydrogenase in cancer patients.
    Etienne MC; Lagrange JL; Dassonville O; Fleming R; Thyss A; Renée N; Schneider M; Demard F; Milano G
    J Clin Oncol; 1994 Nov; 12(11):2248-53. PubMed ID: 7964939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
    Milano G; Chamorey AL
    Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
    Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
    J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
    van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Van Lenthe H; Bakker PJ; Richel DJ; Guchelaar HJ
    Eur J Cancer; 2007 Jan; 43(2):459-65. PubMed ID: 17097873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.